PhaseBio Pharmaceuticals Current Ratio

Current Ratio of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Current Ratio growth rates and interactive chart. The current ratio is a liquidity ratio that measures whether a firm has enough resources to meet its short-term obligations. It is calculated as current assets divided by current liabilities. A ratio below 1 indicates potential trouble for a company, as it doesn't have enough current assets to pay for its short-term liabilities. A ratio above 2 is usually considered healthy.

Highlights and Quick Summary

  • Current Ratio for the quarter ending September 29, 2021 was 3.04 (a -44.43% decrease compared to previous quarter)
  • Year-over-year quarterly Current Ratio increased by 13.29%
  • Annual Current Ratio for 2020 was 2.68 (a -71.13% decrease from previous year)
  • Annual Current Ratio for 2019 was 9.3 (a -32.06% decrease from previous year)
  • Annual Current Ratio for 2018 was 13.68 (a 1651.56% increase from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Current Ratio of PhaseBio Pharmaceuticals

Most recent Current Ratioof PHAS including historical data for past 10 years.

Interactive Chart of Current Ratio of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Current Ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 3.04 5.47 5.29
2020 2.68 4.39 3.58 9.68 2.68
2019 9.3 13.98 16.52 14.24 9.3
2018 13.68 3.25 13.68
2017 0.78
2016 4.6

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.